SI21102A - Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika - Google Patents

Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika Download PDF

Info

Publication number: SI21102A
Authority: SI; Slovenia
Prior art keywords: csf; biologically active; imac; buffer; elution
Prior art date: 2001-12-19

Application number

SI200100322A

Other languages

English (en)

Slovenian (sl)

Inventor

Porekar Vladka Gaberc

Viktor Menart

Original Assignee

LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-19

Filing date

2001-12-19

Publication date

2003-06-30

2001-12-19 Application filed by LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. filed Critical LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.

2001-12-19 Priority to SI200100322A priority Critical patent/SI21102A/sl

2002-12-05 Priority to HR20040572A priority patent/HRP20040572A2/xx

2002-12-05 Priority to BR0215191-0A priority patent/BR0215191A/pt

2002-12-05 Priority to US10/499,315 priority patent/US20050159589A1/en

2002-12-05 Priority to CA2469984A priority patent/CA2469984C/en

2002-12-05 Priority to KR10-2004-7009409A priority patent/KR20040071212A/ko

2002-12-05 Priority to DE60231243T priority patent/DE60231243D1/de

2002-12-05 Priority to HU0402547A priority patent/HUP0402547A3/hu

2002-12-05 Priority to MXPA04006076A priority patent/MXPA04006076A/es

2002-12-05 Priority to PL369669A priority patent/PL207775B1/pl

2002-12-05 Priority to HK04107314.0A priority patent/HK1064681B/en

2002-12-05 Priority to JP2003552802A priority patent/JP4454311B2/ja

2002-12-05 Priority to AT02804876T priority patent/ATE423136T1/de

2002-12-05 Priority to RU2004121982/13A priority patent/RU2358980C2/ru

2002-12-05 Priority to NZ533305A priority patent/NZ533305A/en

2002-12-05 Priority to CNA028254651A priority patent/CN1606568A/zh

2002-12-05 Priority to SI200230822T priority patent/SI1458757T1/sl

2002-12-05 Priority to PCT/EP2002/013810 priority patent/WO2003051922A1/en

2002-12-05 Priority to EP09152902A priority patent/EP2053061A1/de

2002-12-05 Priority to AU2002366275A priority patent/AU2002366275B2/en

2002-12-05 Priority to EP02804876A priority patent/EP1458757B1/de

2002-12-05 Priority to IL16244802A priority patent/IL162448A0/xx

2003-06-30 Publication of SI21102A publication Critical patent/SI21102A/sl

2004-06-01 Priority to ZA200404291A priority patent/ZA200404291B/en

2004-06-10 Priority to IL162448A priority patent/IL162448A/en

2004-07-14 Priority to NO20042967A priority patent/NO20042967L/no

Links

108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 title claims abstract description 206
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 title claims abstract description 206
238000000034 method Methods 0.000 title claims abstract description 95
230000008569 process Effects 0.000 title claims abstract description 55
238000002955 isolation Methods 0.000 title claims abstract description 51
102100021935 C-C motif chemokine 26 Human genes 0.000 claims abstract description 71
101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 claims abstract description 71
238000002523 gelfiltration Methods 0.000 claims abstract description 24
238000005277 cation exchange chromatography Methods 0.000 claims abstract description 14
238000002360 preparation method Methods 0.000 claims abstract description 7
239000000872 buffer Substances 0.000 claims description 72
102000004169 proteins and genes Human genes 0.000 claims description 54
108090000623 proteins and genes Proteins 0.000 claims description 54
239000000243 solution Substances 0.000 claims description 40
210000003000 inclusion body Anatomy 0.000 claims description 26
238000010828 elution Methods 0.000 claims description 24
230000027455 binding Effects 0.000 claims description 18
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims description 16
238000000926 separation method Methods 0.000 claims description 14
101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 claims description 12
238000004587 chromatography analysis Methods 0.000 claims description 12
239000007983 Tris buffer Substances 0.000 claims description 10
238000004153 renaturation Methods 0.000 claims description 10
238000005406 washing Methods 0.000 claims description 10
229910019142 PO4 Inorganic materials 0.000 claims description 9
239000000969 carrier Substances 0.000 claims description 9
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 9
239000010452 phosphate Substances 0.000 claims description 8
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 7
238000002512 chemotherapy Methods 0.000 claims description 6
230000009467 reduction Effects 0.000 claims description 6
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 claims description 6
239000008351 acetate buffer Substances 0.000 claims description 5
208000015181 infectious disease Diseases 0.000 claims description 5
206010011409 Cross infection Diseases 0.000 claims description 4
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 4
NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims description 4
208000004235 neutropenia Diseases 0.000 claims description 4
230000002265 prevention Effects 0.000 claims description 4
206010059482 Neutropenic infection Diseases 0.000 claims description 3
238000004925 denaturation Methods 0.000 claims description 3
230000036425 denaturation Effects 0.000 claims description 3
201000010099 disease Diseases 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
239000012149 elution buffer Substances 0.000 claims description 3
102000037865 fusion proteins Human genes 0.000 claims description 3
108020001507 fusion proteins Proteins 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
238000002428 photodynamic therapy Methods 0.000 claims description 3
230000003248 secreting effect Effects 0.000 claims description 3
239000006228 supernatant Substances 0.000 claims description 3
208000028399 Critical Illness Diseases 0.000 claims description 2
102000004127 Cytokines Human genes 0.000 claims description 2
108090000695 Cytokines Proteins 0.000 claims description 2
208000002633 Febrile Neutropenia Diseases 0.000 claims description 2
208000012902 Nervous system disease Diseases 0.000 claims description 2
206010033661 Pancytopenia Diseases 0.000 claims description 2
206010040943 Skin Ulcer Diseases 0.000 claims description 2
206010072170 Skin wound Diseases 0.000 claims description 2
208000007536 Thrombosis Diseases 0.000 claims description 2
230000003110 anti-inflammatory effect Effects 0.000 claims description 2
230000000259 anti-tumor effect Effects 0.000 claims description 2
239000007979 citrate buffer Substances 0.000 claims description 2
230000002860 competitive effect Effects 0.000 claims description 2
229910052802 copper Inorganic materials 0.000 claims description 2
230000010437 erythropoiesis Effects 0.000 claims description 2
210000004602 germ cell Anatomy 0.000 claims description 2
230000003394 haemopoietic effect Effects 0.000 claims description 2
230000035876 healing Effects 0.000 claims description 2
210000000987 immune system Anatomy 0.000 claims description 2
238000001802 infusion Methods 0.000 claims description 2
210000000265 leukocyte Anatomy 0.000 claims description 2
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 2
229910052759 nickel Inorganic materials 0.000 claims description 2
239000008363 phosphate buffer Substances 0.000 claims description 2
238000001959 radiotherapy Methods 0.000 claims description 2
238000011084 recovery Methods 0.000 claims description 2
238000004904 shortening Methods 0.000 claims description 2
231100000019 skin ulcer Toxicity 0.000 claims description 2
229910052725 zinc Inorganic materials 0.000 claims description 2
239000007853 buffer solution Substances 0.000 claims 2
BTLHODXEDLCLAD-VKHMYHEASA-N (2s)-2-(carboxymethylamino)butanedioic acid Chemical compound OC(=O)CN[C@H](C(O)=O)CC(O)=O BTLHODXEDLCLAD-VKHMYHEASA-N 0.000 claims 1
206010029803 Nosocomial infection Diseases 0.000 claims 1
206010040047 Sepsis Diseases 0.000 claims 1
206010040070 Septic Shock Diseases 0.000 claims 1
239000002253 acid Substances 0.000 claims 1
208000037976 chronic inflammation Diseases 0.000 claims 1
208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
230000000069 prophylactic effect Effects 0.000 claims 1
230000036303 septic shock Effects 0.000 claims 1
239000012535 impurity Substances 0.000 abstract description 6
239000013522 chelant Substances 0.000 abstract description 4
238000001042 affinity chromatography Methods 0.000 abstract description 2
238000009776 industrial production Methods 0.000 abstract description 2
229910052751 metal Inorganic materials 0.000 abstract description 2
239000002184 metal Substances 0.000 abstract description 2
235000018102 proteins Nutrition 0.000 description 53
241000588724 Escherichia coli Species 0.000 description 16
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
238000000746 purification Methods 0.000 description 14
230000004071 biological effect Effects 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
229920002684 Sepharose Polymers 0.000 description 12
150000002500 ions Chemical class 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
125000002091 cationic group Chemical group 0.000 description 7
239000003599 detergent Substances 0.000 description 7
239000000203 mixture Substances 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
230000008901 benefit Effects 0.000 description 6
238000013375 chromatographic separation Methods 0.000 description 6
239000003398 denaturant Substances 0.000 description 6
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 5
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
239000012505 Superdex™ Substances 0.000 description 4
238000002835 absorbance Methods 0.000 description 4
230000000975 bioactive effect Effects 0.000 description 4
230000008859 change Effects 0.000 description 4
238000000502 dialysis Methods 0.000 description 4
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
229910021645 metal ion Inorganic materials 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
108010029961 Filgrastim Proteins 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
239000004202 carbamide Substances 0.000 description 3
239000000539 dimer Substances 0.000 description 3
235000014304 histidine Nutrition 0.000 description 3
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 3
238000005498 polishing Methods 0.000 description 3
230000028327 secretion Effects 0.000 description 3
229910052720 vanadium Inorganic materials 0.000 description 3
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
108010062867 Lenograstim Proteins 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
239000012506 Sephacryl® Substances 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
150000001413 amino acids Chemical group 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
238000011210 chromatographic step Methods 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
229960004177 filgrastim Drugs 0.000 description 2
210000003958 hematopoietic stem cell Anatomy 0.000 description 2
229960002618 lenograstim Drugs 0.000 description 2
239000000463 material Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 1
XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
102220519361 Coatomer subunit alpha_C17S_mutation Human genes 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108010093488 His-His-His-His-His-His Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
102000000646 Interleukin-3 Human genes 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
230000004913 activation Effects 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000003196 chaotropic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940047120 colony stimulating factors Drugs 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
229940076264 interleukin-3 Drugs 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
239000002609 medium Substances 0.000 description 1
IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 1
125000000896 monocarboxylic acid group Chemical group 0.000 description 1
239000000178 monomer Substances 0.000 description 1
229940029345 neupogen Drugs 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000006920 protein precipitation Effects 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
229940117986 sulfobetaine Drugs 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Analytical Chemistry (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Compounds Of Unknown Constitution (AREA)

SI200100322A 2001-12-19 2001-12-19 Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika SI21102A (sl)

Priority Applications (25)

Application Number	Priority Date	Filing Date	Title
SI200100322A SI21102A (sl)	2001-12-19	2001-12-19	Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
JP2003552802A JP4454311B2 (ja)	2001-12-19	2002-12-05	生物学的に活性な顆粒球コロニー刺激因子の精製および／または単離方法
RU2004121982/13A RU2358980C2 (ru)	2001-12-19	2002-12-05	Способ очистки и/или выделения биологически активного гранулоцитарного колониестимулирующего фактора
US10/499,315 US20050159589A1 (en)	2001-12-19	2002-12-05	Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor
CA2469984A CA2469984C (en)	2001-12-19	2002-12-05	Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor
KR10-2004-7009409A KR20040071212A (ko)	2001-12-19	2002-12-05	생물학적 활성 과립구 콜로니 자극 인자의 정제 및(또는)단리 방법
DE60231243T DE60231243D1 (de)	2001-12-19	2002-12-05	Prozess für die aufreinigung und isolierung von biologisch-aktivem granulozyten-koloniestimulierungsfaktor
HU0402547A HUP0402547A3 (en)	2001-12-19	2002-12-05	Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor
MXPA04006076A MXPA04006076A (es)	2001-12-19	2002-12-05	Proceso para la purificacion y/o aislamiento del factor estimulante de colonias de granulocitos biologicamente activos.
PL369669A PL207775B1 (pl)	2001-12-19	2002-12-05	Sposób izolowania biologicznie czynnego poprawnie zwiniętego czynnika stymulującego kolonie granulocytów (G-CSF)
HK04107314.0A HK1064681B (en)	2001-12-19	2002-12-05	Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor
HR20040572A HRP20040572A2 (en)	2001-12-19	2002-12-05	Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor
AT02804876T ATE423136T1 (de)	2001-12-19	2002-12-05	Prozess für die aufreinigung und isolierung von biologisch-aktivem granulozyten- koloniestimulierungsfaktor
CNA028254651A CN1606568A (zh)	2001-12-19	2002-12-05	生物活性粒细胞集落刺激因子的纯化和/或分离方法
NZ533305A NZ533305A (en)	2001-12-19	2002-12-05	Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor
EP02804876A EP1458757B1 (de)	2001-12-19	2002-12-05	Prozess für die aufreinigung und isolierung von biologisch-aktivem granulozyten-koloniestimulierungsfaktor
SI200230822T SI1458757T1 (sl)	2001-12-19	2002-12-05	Postopek za äśiĺ äśenje in/ali izolacijo bioloĺ ko aktivnega rastnega dejavnika za granulocite (g-csf)
PCT/EP2002/013810 WO2003051922A1 (en)	2001-12-19	2002-12-05	Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor
EP09152902A EP2053061A1 (de)	2001-12-19	2002-12-05	Prozess für die aufreinigung und isolierung von biologisch-aktivem granulozyten-koloniestimulierungsfaktor
AU2002366275A AU2002366275B2 (en)	2001-12-19	2002-12-05	Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor
BR0215191-0A BR0215191A (pt)	2001-12-19	2002-12-05	Processo para a purificação e/ou isolamento de fator de estimulação de colÈnia de granulócito biologicamente ativo
IL16244802A IL162448A0 (en)	2001-12-19	2002-12-05	Process for the purification and/orisolation of biologically active granulocyte colony stimulating factor
ZA200404291A ZA200404291B (en)	2001-12-19	2004-06-01	Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor.
IL162448A IL162448A (en)	2001-12-19	2004-06-10	Process for the purification and isolation of biologically active granulocyte colony stimulating factor
NO20042967A NO20042967L (no)	2001-12-19	2004-07-14	Fremgangsmate for rensing og/eller isolasjon av biologisk aktiv granulocyt-koloni-stimulerende-faktor

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SI200100322A SI21102A (sl)	2001-12-19	2001-12-19	Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika

Publications (1)

Publication Number	Publication Date
SI21102A true SI21102A (sl)	2003-06-30

Family

ID=20433022

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI200100322A SI21102A (sl)	2001-12-19	2001-12-19	Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
SI200230822T SI1458757T1 (sl)	2001-12-19	2002-12-05	Postopek za äśiĺ äśenje in/ali izolacijo bioloĺ ko aktivnega rastnega dejavnika za granulocite (g-csf)

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SI200230822T SI1458757T1 (sl)	2001-12-19	2002-12-05	Postopek za äśiĺ äśenje in/ali izolacijo bioloĺ ko aktivnega rastnega dejavnika za granulocite (g-csf)

Country Status (21)

Country	Link
US (1)	US20050159589A1 (de)
EP (2)	EP2053061A1 (de)
JP (1)	JP4454311B2 (de)
KR (1)	KR20040071212A (de)
CN (1)	CN1606568A (de)
AT (1)	ATE423136T1 (de)
AU (1)	AU2002366275B2 (de)
BR (1)	BR0215191A (de)
CA (1)	CA2469984C (de)
DE (1)	DE60231243D1 (de)
HR (1)	HRP20040572A2 (de)
HU (1)	HUP0402547A3 (de)
IL (2)	IL162448A0 (de)
MX (1)	MXPA04006076A (de)
NO (1)	NO20042967L (de)
NZ (1)	NZ533305A (de)
PL (1)	PL207775B1 (de)
RU (1)	RU2358980C2 (de)
SI (2)	SI21102A (de)
WO (1)	WO2003051922A1 (de)
ZA (1)	ZA200404291B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI21273A (sl) *	2002-07-31	2004-02-29	LEK farmacevtska dru�ba d.d.	Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
DK1439191T3 (da) *	2004-01-19	2006-08-14	Ares Trading Sa	Proces til oprensning af bakterielt udtrykte proteiner
EP1803464A4 (de) *	2004-09-17	2009-09-09	Cellgentech Inc	Topisches präparat zur behandlung von hautgeschwüren
WO2006086822A1 (en) *	2005-02-15	2006-08-24	Apollo Life Sciences Limited	A molecule and chimeric molecules thereof
WO2006097944A2 (en) *	2005-03-17	2006-09-21	Zenotech Laboratories Limited	Process for the purification of recombinant granulocyte-colony stimulating factor
DE102005033250A1 (de) *	2005-07-15	2007-01-18	Bioceuticals Arzneimittel Ag	Verfahren zur Reinigung von G-CSF
DE202006020194U1 (de)	2006-03-01	2007-12-06	Bioceuticals Arzneimittel Ag	G-CSF-Flüssigformulierung
EP1878739A1 (de)	2006-07-14	2008-01-16	LEK Pharmaceuticals D.D.	Einstufige IMAC (MCAC) Aufreinigung von Proteinen
WO2008096370A2 (en) *	2007-02-05	2008-08-14	Natco Pharma Limited	An efficient and novel purification method of recombinant hg-csf
MX2010002448A (es)	2007-08-27	2010-10-04	Biogenerix Ag	Formulacion liquida del g-csf conjugado.
JP2009073819A (ja) *	2007-08-29	2009-04-09	Fujifilm Corp	生理活性物質の精製方法
EP2443135A1 (de) *	2009-06-16	2012-04-25	Lupin Ltd.	Verfahren zur aufreinigung von rekombinantem humanem granulozyten-kolonie stimulierendem faktor
EP3366692A1 (de)	2009-06-22	2018-08-29	Amgen, Inc	Proteinneufaltung mit einem chemisch gesteuerten redoxzustand
AU2010266093B2 (en)	2009-06-25	2013-06-27	Amgen Inc.	Capture purification processes for proteins expressed in a non-mammalian system
KR101951446B1 (ko) *	2010-03-30	2019-02-22	옥타파마 아게	성장 인자 단백질을 정제하는 방법
CN107915769A (zh)	2011-03-29	2018-04-17	葛兰素史密斯克莱有限责任公司	用于蛋白纯化的缓冲液体系
CN103215340A (zh) *	2012-01-19	2013-07-24	江苏粒福特生物科技有限公司	一种新颖的粒细胞制备及其抗癌活性检测方法
HUP1200171A1 (hu)	2012-03-19	2013-09-30	Richter Gedeon Nyrt	Módszerek polipeptidek elõállítására
HUP1200172A2 (en)	2012-03-19	2013-10-28	Richter Gedeon Nyrt	Methods for refolding g-csf from inclusion bodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS61227526A (ja)	1984-07-25	1986-10-09	Chugai Pharmaceut Co Ltd	新規なコロニー刺激因子
ATE65798T1 (de)	1985-02-08	1991-08-15	Chugai Pharmaceutical Co Ltd	Menschlicher granuloxcyt-koloniestimulierungsfaktor.
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
DK203187A (da)	1986-04-22	1987-10-23	Immunex Corp	Human g-csf proteinekspression
KR0133561B1 (ko) *	1988-05-13	1998-04-21	스티븐 엠. 오드레	과립구 군체 자극인자의 정제방법
US5055555A (en)	1989-01-05	1991-10-08	Helmut Sassenfeld	Purification of G-CSF
US5169936A (en)	1989-04-14	1992-12-08	Biogen, Inc.	Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
US5932102A (en)	1998-01-12	1999-08-03	Schering Corporation	Immobilized metal, affinity chromatography
FR2796071B1 (fr) *	1999-07-08	2001-09-07	Hoechst Marion Roussel Inc	Procede de purification de facteur de stimulation de colonies de granulocytes

2001
- 2001-12-19 SI SI200100322A patent/SI21102A/sl not_active IP Right Cessation
2002
- 2002-12-05 HR HR20040572A patent/HRP20040572A2/xx not_active Application Discontinuation
- 2002-12-05 IL IL16244802A patent/IL162448A0/xx unknown
- 2002-12-05 US US10/499,315 patent/US20050159589A1/en not_active Abandoned
- 2002-12-05 EP EP09152902A patent/EP2053061A1/de not_active Withdrawn
- 2002-12-05 RU RU2004121982/13A patent/RU2358980C2/ru not_active IP Right Cessation
- 2002-12-05 AT AT02804876T patent/ATE423136T1/de active
- 2002-12-05 JP JP2003552802A patent/JP4454311B2/ja not_active Expired - Fee Related
- 2002-12-05 WO PCT/EP2002/013810 patent/WO2003051922A1/en not_active Ceased
- 2002-12-05 MX MXPA04006076A patent/MXPA04006076A/es active IP Right Grant
- 2002-12-05 KR KR10-2004-7009409A patent/KR20040071212A/ko not_active Ceased
- 2002-12-05 DE DE60231243T patent/DE60231243D1/de not_active Expired - Lifetime
- 2002-12-05 CA CA2469984A patent/CA2469984C/en not_active Expired - Fee Related
- 2002-12-05 AU AU2002366275A patent/AU2002366275B2/en not_active Ceased
- 2002-12-05 PL PL369669A patent/PL207775B1/pl unknown
- 2002-12-05 BR BR0215191-0A patent/BR0215191A/pt not_active Application Discontinuation
- 2002-12-05 SI SI200230822T patent/SI1458757T1/sl unknown
- 2002-12-05 EP EP02804876A patent/EP1458757B1/de not_active Expired - Lifetime
- 2002-12-05 CN CNA028254651A patent/CN1606568A/zh active Pending
- 2002-12-05 NZ NZ533305A patent/NZ533305A/en unknown
- 2002-12-05 HU HU0402547A patent/HUP0402547A3/hu unknown
2004
- 2004-06-01 ZA ZA200404291A patent/ZA200404291B/en unknown
- 2004-06-10 IL IL162448A patent/IL162448A/en not_active IP Right Cessation
- 2004-07-14 NO NO20042967A patent/NO20042967L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2469984A1 (en)	2003-06-26
PL369669A1 (en)	2005-05-02
AU2002366275A1 (en)	2003-06-30
SI1458757T1 (sl)	2009-10-31
EP1458757B1 (de)	2009-02-18
US20050159589A1 (en)	2005-07-21
DE60231243D1 (de)	2009-04-02
KR20040071212A (ko)	2004-08-11
ZA200404291B (en)	2005-08-05
IL162448A0 (en)	2005-11-20
ATE423136T1 (de)	2009-03-15
EP1458757A1 (de)	2004-09-22
EP2053061A1 (de)	2009-04-29
CA2469984C (en)	2014-05-20
IL162448A (en)	2010-12-30
RU2358980C2 (ru)	2009-06-20
HUP0402547A3 (en)	2010-01-28
RU2004121982A (ru)	2005-04-20
HUP0402547A2 (hu)	2005-03-29
HK1064681A1 (en)	2005-02-04
WO2003051922A1 (en)	2003-06-26
JP4454311B2 (ja)	2010-04-21
NZ533305A (en)	2005-11-25
NO20042967L (no)	2004-09-07
BR0215191A (pt)	2004-11-16
AU2002366275B2 (en)	2009-04-02
JP2005525304A (ja)	2005-08-25
MXPA04006076A (es)	2005-02-24
CN1606568A (zh)	2005-04-13
HRP20040572A2 (en)	2005-06-30
PL207775B1 (pl)	2011-01-31

Legal Events

Date	Code	Title	Description
2005-01-10	IF	Valid on the event date
2012-02-29	KO00	Lapse of patent	Effective date: 20120106

Publication	Publication Date	Title
SI21102A (sl)	2003-06-30	Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
BG65449B1 (bg)	2008-08-29	Еритропоетинови производни
ES3002087T3 (en)	2025-03-06	A novel process for purification of rhu-gcsf
EP2051989A1 (de)	2009-04-29	Einstufige imac-(mcac-)aufreinigung von proteinen
JPH03193736A (ja)	1991-08-23	ヒトインターロイキン２の活性を有するポリペプチドからなることを特徴とする白血病を治療するための医薬組成物
ES2322819T5 (es)	2021-02-11	Procedimiento de purificación de G-CSF
EP2341061B1 (de)	2013-07-31	Neuartiges Verfahren zur Herstellung von G-CSF
IL90975A (en)	1994-11-28	Non-glycosylated, recombinant human il2 in reduced form, the process for obtaining it and its use as a medicament
RU2278870C2 (ru)	2006-06-27	Способ получения, выделения, очистки и стабилизации рекомбинантного гранулоцитарного колониестимулирующего фактора человека, пригодного для медицинского применения, и иммунобиологическое средство на его основе
IE61444B1 (en)	1994-11-02	Process for preparing and purifying interferon
MXPA06006356A (es)	2006-08-23	Proceso para purificar interferon beta.
KR100531670B1 (ko)	2005-11-28	인체 인터페론 알파의 제조방법
JPWO1992014832A1 (ja)	1993-04-02	ヒトｂｃｄｆの精製法
WO1992014832A1 (fr)	1992-09-03	Procedes pour la purification de fdlb humains
HK1064681B (en)	2009-10-23	Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor
WO2016146629A1 (en)	2016-09-22	A process for preparing g-csf (granulocyte colony stimulating factor)
EP0446850B1 (de)	1996-01-24	Verfahren zur Herstellung von rekombinantem Humaninterferon-beta in reiner Form
US20220195002A1 (en)	2022-06-23	Process for preparing granulocyte-colony stimulating factor
WO2026013498A1 (en)	2026-01-15	Method for purification of hyaluronidase enzyme